2015-03-18 – News Release – InMed Pharmaceuticals Inc. (IN:CSE) has initiated a program to identify and evaluate cannabinoid compounds for the treatment of chronic orofacial pain. Initial drug discovery and preclinical development are currently under way in collaboration with members of the faculty of pharmaceutical sciences at the University of British Columbia. The work is being funded by a grant from Mitacs, a leading Canadian organization that accelerates innovative projects through strategic academic and industry collaboration.
Dr. Sazzad Hossain, chief scientific officer, stated: “Pain in the orofacial region is one of the more complex and difficult-to-treat conditions for patients and clinicians. Current treatments are limited in terms of efficacy and are fraught with considerable side effects. Recent advances in cannabinoid pharmacology have renewed hope for these patients with the exciting prospect of safer, more effective cannabis-based treatments. Under this collaboration, Inmed will investigate the role of cannabinoid receptors in chronic orofacial pain, including neuropathic pain, muscle pain and arthritis of the jaw joint.”
A Mitacs grant was awarded to Dr. Hayes Wong, a PhD-level researcher, with extensive experience in developing orofacial models of pain. Dr. Wong will be working with Prof. Brian Cairns, a specialist in research for chronic pain above the neck. In conjunction with InMed, the Mitacs grant will be utilized to screen selected InMed compounds in orofacial pain models.
About Mitacs
Mitacs is a national, private, not-for-profit organization that develops the next generation of innovators with vital scientific and business skills through a suite of unique research and training programs, such as Mitacs Accelerate, Elevate, Step, Enterprise and Globalink. In partnership with companies, government and universities, Mitacs is supporting a new economy using Canada’s most valuable resource — its people.
We seek Safe Harbor.